Amvuttra
ProductHeard on podcasts recently
Amvuttra is a prescription medicine developed by Alnylam Pharmaceuticals for treating transthyretin-mediated amyloidosis, including cardiomyopathy associated with ATTR-CM.
Discussed inMarkets100%
Rank this week
—
Not in this week’s list
Share of the conversation
—
Reach this week
—
Tone this week
—
Not enough signal yet (fewer than 3 episodes scored).
Share of the conversation
Mentions of Amvuttra per 1,000 mentions of anything, 7-day rolling, all podcasts.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Oct 30 | 0.01‰ | 1 |
| Nov 13 | 0.03‰ | 4 |
Who is saying what about Amvuttra
Verified quotes from the last 90 days: who made the most claims, and which way they leaned.
- Elaine Chen1 claim on 1 show
“Alnylam is struggling with getting more prescriptions.”
The Readout Loud · Nov 13 ↗ - Adam Feuerstein1 claim on 1 show
“Amputra is a blockbuster drug.”
The Readout Loud · Nov 13 ↗ - Paul Matteis1 claim on 1 show
“The Almalum launch with Ambutra has kind of petered out”
Biotech Hangout · Nov 13 ↗
Discussed alongside
Names that come up in the same conversations as Amvuttra.
Embed this
Paste this on your site to show Amvuttra's current trend:
<iframe src="https://podlume.ai/embed/e/amvuttra" width="360" height="220" style="border:0" loading="lazy" title="Amvuttra on PodLume Trends"></iframe>